Literature DB >> 21558853

Time perception of cancer patients without evidence of disease and advanced cancer patients in a palliative, end-of-life-care setting.

Hanneke W M van Laarhoven1, Johannes Schilderman, Constans A H H V M Verhagen, Judith B Prins.   

Abstract

BACKGROUND: Time perception may be an important factor influencing distress of cancer patients. However, no comparative studies have been performed for cancer patients without evidence of disease and advanced cancer patients in the palliative, end-of-life-care setting.
OBJECTIVE: The objectives of the study were to assess time perception in disease-free and advanced cancer patients and examine the relation of time perception with patients' distress.
METHODS: A descriptive research design was used. Ninety-six disease-free and 63 advanced cancer patients filled out Cottle's Circle Test to assess time coherence and time dominance, Cottle's Line Test to assess temporal extension and Bayes' question on speed of time, the European Organisation for Research-and-Treatment of Cancer QOL-Questionnaire version 2.0, Beck's Depression Inventory for primary care, and Beck's Hopelessness-Scale.
RESULTS: In patients without evidence of disease, future dominance was most often observed, whereas in advanced cancer patients, the present was the dominant time segment. In both groups, a focus on the past was associated with distress. In contrast with patients without evidence of disease, advanced cancer patients perceived time as moving slowly, and this was correlated with distress.
CONCLUSIONS: The time perception of cancer patients without evidence of disease and advanced cancer patients is significantly different and is related to distress. IMPLICATIONS FOR PRACTICE: The observed relation between a focus on the past and distress gives room for interventions of nurses and other healthcare professionals. Specific attention is needed for differences between cancer patients without evidence of disease and advanced cancer patients.

Entities:  

Mesh:

Year:  2011        PMID: 21558853     DOI: 10.1097/NCC.0b013e31820f4eb7

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  7 in total

1.  Past, present and future, the experience of time during examination for malignant brain tumor: a qualitative observational study.

Authors:  Rikke Guldager; Pernille Vinding Hansen; Morten Ziebell
Journal:  Acta Neurochir (Wien)       Date:  2021-01-02       Impact factor: 2.216

2.  Experience of Time and Subjective Age When Facing a Limited Lifetime: The Case of Older Adults with Advanced Cancer.

Authors:  Katsiaryna Laryionava; Anton Schönstein; Pia Heußner; Wolfgang Hiddemann; Eva C Winkler; Hans-Werner Wahl
Journal:  J Aging Health       Date:  2021-12-30

3.  A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.

Authors:  Panagiotis Petrou; Michael A Talias
Journal:  Cost Eff Resour Alloc       Date:  2014-05-03

4.  Do Future Limitation Perspective in Cancer Patients Predict Fear of Cancer Recurrence, Mental Distress, and the Ventromedial Prefrontal Cortex Activity?

Authors:  Jia Zhou; Pan Feng; Xiaofei Lu; Xingping Han; Yanli Yang; Jingjing Song; Guangyu Jiang; Yong Zheng
Journal:  Front Psychol       Date:  2018-03-28

Review 5.  Dispositional orientation to the present and future and its role in pro-environmental behavior and sustainability.

Authors:  Marc Wittmann; Anna Sircova
Journal:  Heliyon       Date:  2018-10-26

6.  Bad Healthy State Compress Temporal Extension Both in Past and Future Orientations.

Authors:  Jia Zhou; Xingping Han; Juan Fan; Pan Feng; Jingjing Song; Guangyu Jiang; Yong Zheng
Journal:  Front Psychol       Date:  2018-09-11

7.  Formalin-induced and neuropathic pain altered time estimation in a temporal bisection task in rats.

Authors:  Xinhe Liu; Ning Wang; Jinyan Wang; Fei Luo
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.